Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 12/20 | 0.75 |
| ▸ | GCGR | P47871 | 8/20 | 0.71 |
| ▸ | GIPR | P48546 | 5/20 | 0.70 |
| ▸ | PTH1R | Q03431 | 5/20 | 0.68 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL29533662 | 1.00 | GLP1R (0.75) | GLP1RGCGRGIPRPTH1RCXCR4 | |
| SCHEMBL29376189 | 0.99 | GLP1R (0.76) | GLP1RGCGRGIPRPTH1R | |
| SCHEMBL29399148 | 0.99 | GLP1R (0.76) | GLP1RGCGRGIPRPTH1R | |
| SCHEMBL29359393 | 0.99 | GLP1R (0.76) | GLP1RGCGRGIPRPTH1R | |
| SCHEMBL31759052 | 0.98 | GLP1R (0.75) | GLP1RGCGRGIPRPTH1R | |
| SCHEMBL30874225 | 0.97 | GLP1R (0.73) | GLP1RGCGRGIPRPTH1R | |
| SCHEMBL29395085 | 0.96 | GLP1R (0.73) | GLP1RGCGRGIPRCXCR4 | |
| SCHEMBL30473776 | 0.96 | GLP1R (0.75) | GLP1RGCGRGIPR | |
| SCHEMBL30473781 | 0.96 | GLP1R (0.73) | GLP1RGCGRGIPRPTH1R | |
| SCHEMBL30473787 | 0.96 | GLP1R (0.75) | GLP1RGCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034221-A1 | BUFFERED FORMULATIONS OF EXENDIN (9-39) | AMYLYX PHARMACEUTICALS INC (US) | 2026-02-05 | — | — | US | claimed |
| EP-4591853-A1 | BUFFERED FORMULATIONS OF EXENDIN (9-39) | Amylyx Pharmaceuticals, Inc. (US) | 2025-07-30 | — | — | EP | claimed |
| EP-3541366-B1 | BUFFERED FORMULATIONS OF EXENDIN (9-39) | AMYLYX PHARMACEUTICALS INC (US) | 2024-12-25 | — | — | EP | claimed |
| US-11738086-B2 | Methods of using buffered formulations of exendin (9-39) | EIGER BIOPHARMACEUTICALS, INC. (US) | 2023-08-29 | — | — | US | claimed |
| US-20260034221-A1 | BUFFERED FORMULATIONS OF EXENDIN (9-39) | AMYLYX PHARMACEUTICALS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250255935-A1 | TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA WITH GLP-1 ANTAGONIST EXENDIN(9-39) | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-08-14 | — | — | US | disclosed |
| EP-4591853-A1 | BUFFERED FORMULATIONS OF EXENDIN (9-39) | Amylyx Pharmaceuticals, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250082730-A1 | TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA WITH EXENDIN (9-39) | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-03-13 | — | — | US | disclosed |
| US-12220444-B2 | Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39) | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-02-11 | — | — | US | disclosed |
| EP-3541366-B1 | BUFFERED FORMULATIONS OF EXENDIN (9-39) | AMYLYX PHARMACEUTICALS INC (US) | 2024-12-25 | — | — | EP | disclosed |
| US-12102663-B2 | Treatment of post-bariatric hypoglycemia with exendin (9-39) | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-10-01 | — | — | US | disclosed |
| WO-2024042518-A1 | GLP-1 RECEPTOR ANTAGONIST AND METHODS OF USE THEREOF | M. ARKIN (1999) LTD (IL) | 2024-02-29 | — | — | WO | disclosed |
| US-20240042035-A1 | Buffered Formulations Of Exendin (9-39) | AMYLYX PHARMACEUTICALS, INC. | 2024-02-08 | — | — | US | disclosed |
| US-20240000894-A1 | TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA WITH EXENDIN (9-39) | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-01-04 | — | — | US | disclosed |
| US-20230346890-A1 | TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA WITH GLP-1 ANTAGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| US-11738086-B2 | Methods of using buffered formulations of exendin (9-39) | EIGER BIOPHARMACEUTICALS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11622995-B2 | Treatment of post-bariatric hypoglycemia with GLP-1 antagonists | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-04-11 | — | — | US | disclosed |
| US-11617782-B2 | Treatment of post-bariatric hypoglycemia with exendin (9-39) | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-04-04 | — | — | US | disclosed |
| EP-3978011-A1 | TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA WITH GLP-1 ANTAGONISTS | The Board of Trustees of the Leland Stanford Junior University (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034221-A1 | BUFFERED FORMULATIONS OF EXENDIN (9-39) | SLC5A1, SLC5A2, IAPP | GLP1R 4/4885GCGR 80/4885GIPR 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.